Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Multiple sclerosis (MS)

Prostate-specific membrane antigen (PSMA; FOLH1; GCPII)

Human and mouse studies suggest inhibiting GCPII could help treat cognitive impairments associated with MS. In newly diagnosed patients with relapsing-remitting MS, magnetic resonance spectroscopy of brains showed that low levels of N-acetylaspartylglutamate (NAAG) correlated with cognitive dysfunction. In mice with experimental autoimmune encephalomyelitis (EAE), increasing levels of NAAG with a GCPII inhibitor did not affect physical disease symptoms but increased cognitive functions, including memory and learning, compared with vehicle control. Next steps include identifying new GCPII inhibitors or delivery vehicles.

SciBX 5(47); doi:10.1038/scibx.2012.1227
Published online Dec. 6, 2012

Patent application filed; available for licensing

Rahn, K.A. et al. Proc. Natl. Acad. Sci. USA; published online Nov. 19, 2012;
doi:10.1073/pnas.1209934109
Contact: Adam I. Kaplin, The Johns Hopkins University, Baltimore, Md.
e-mail:

akaplin@jhmi.edu
Contact: Barbara S. Slusher, same affiliation as above
e-mail:

bslusher@jhmi.edu